APO Research

APO RESEARCH · REPORT

Ioversol Injection

Selected research

Market Outlook & Growth Opportunities

Global Ioversol Injection Market Outlook and Growth Opportunities 2026

Market perspective

The global Ioversol Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Ioversol Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Ioversol Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Ioversol Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Ioversol Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Ioversol Injection market include GUERBET, Zhejiang Starry Pharmaceutical, Hengrui Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Neptunus Bio-pharmaceutical, Liebel-Flarsheim Company LLC and Bracco Imaging S.p.A., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Ioversol Injection market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Ioversol Injection and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Ioversol Injection revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Ioversol Injection market.

Ioversol Injection Segment by Company

GUERBET

Zhejiang Starry Pharmaceutical

Hengrui Pharmaceuticals

Bayer HealthCare Pharmaceuticals

Neptunus Bio-pharmaceutical

Liebel-Flarsheim Company LLC

Bracco Imaging S.p.A.

Ioversol Injection Segment by Type

50mL

75mL

100mL

125mL

Ioversol Injection Segment by Application

Hospital

Clinic

Others

Ioversol Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Ioversol Injection status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Ioversol Injection key companies, revenue, market share, and recent developments.

3. To split the Ioversol Injection breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Ioversol Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Ioversol Injection significant trends, drivers, influence factors in global and regions.

6. To analyze Ioversol Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ioversol Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ioversol Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ioversol Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Ioversol Injection industry.

Chapter 3: Detailed analysis of Ioversol Injection company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Ioversol Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Ioversol Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Ioversol Injection Industry Trends Table 2. Ioversol Injection Industry Drivers Table 3. Ioversol Injection Industry Opportunities and Challenges Table 4. Ioversol Injection Industry Restraints Table 5. Global Ioversol Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Ioversol Injection Revenue Share by Company (2021-2026) Table 7. Global Ioversol Injection Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Ioversol Injection Key Company Manufacturing Base & Headquarters Table 9. Global Ioversol Injection Company, Product Type & Application Table 10. Global Ioversol Injection Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Ioversol Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of 50mL Table 15. Significant Companies of 75mL Table 16. Significant Companies of 100mL Table 17. Significant Companies of 125mL Table 18. Global Ioversol Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Ioversol Injection Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Ioversol Injection Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Ioversol Injection Sales Value Share by Type (2021-2026) Table 22. Global Ioversol Injection Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Table 24. Significant Companies of Clinic Table 25. Significant Companies of Others Table 26. Global Ioversol Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Ioversol Injection Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Ioversol Injection Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Ioversol Injection Sales Value Share by Application (2021-2026) Table 30. Global Ioversol Injection Sales Value Share by Application (2027-2032) Table 31. Global Ioversol Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Ioversol Injection Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Ioversol Injection Sales Value Share by Region (2021-2026) Table 34. Global Ioversol Injection Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Ioversol Injection Sales Value Share by Region (2027-2032) Table 36. Global Ioversol Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Ioversol Injection Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Ioversol Injection Sales Value Market Share by Country (2021-2026) Table 39. Global Ioversol Injection Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Ioversol Injection Sales Value Market Share by Country (2027-2032) Table 41. GUERBET Company Information Table 42. GUERBET Business Overview Table 43. GUERBET Ioversol Injection Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. GUERBET Ioversol Injection Product Portfolio Table 45. GUERBET Recent Development Table 46. Zhejiang Starry Pharmaceutical Company Information Table 47. Zhejiang Starry Pharmaceutical Business Overview Table 48. Zhejiang Starry Pharmaceutical Ioversol Injection Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Zhejiang Starry Pharmaceutical Ioversol Injection Product Portfolio Table 50. Zhejiang Starry Pharmaceutical Recent Development Table 51. Hengrui Pharmaceuticals Company Information Table 52. Hengrui Pharmaceuticals Business Overview Table 53. Hengrui Pharmaceuticals Ioversol Injection Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Hengrui Pharmaceuticals Ioversol Injection Product Portfolio Table 55. Hengrui Pharmaceuticals Recent Development Table 56. Bayer HealthCare Pharmaceuticals Company Information Table 57. Bayer HealthCare Pharmaceuticals Business Overview Table 58. Bayer HealthCare Pharmaceuticals Ioversol Injection Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Bayer HealthCare Pharmaceuticals Ioversol Injection Product Portfolio Table 60. Bayer HealthCare Pharmaceuticals Recent Development Table 61. Neptunus Bio-pharmaceutical Company Information Table 62. Neptunus Bio-pharmaceutical Business Overview Table 63. Neptunus Bio-pharmaceutical Ioversol Injection Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Neptunus Bio-pharmaceutical Ioversol Injection Product Portfolio Table 65. Neptunus Bio-pharmaceutical Recent Development Table 66. Liebel-Flarsheim Company LLC Company Information Table 67. Liebel-Flarsheim Company LLC Business Overview Table 68. Liebel-Flarsheim Company LLC Ioversol Injection Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Liebel-Flarsheim Company LLC Ioversol Injection Product Portfolio Table 70. Liebel-Flarsheim Company LLC Recent Development Table 71. Bracco Imaging S.p.A. Company Information Table 72. Bracco Imaging S.p.A. Business Overview Table 73. Bracco Imaging S.p.A. Ioversol Injection Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Bracco Imaging S.p.A. Ioversol Injection Product Portfolio Table 75. Bracco Imaging S.p.A. Recent Development Table 76. Research Programs/Design for This Report Table 77. Authors List of This Report Table 78. Secondary Sources Table 79. Primary Sources List of Figures Figure 1. Ioversol Injection Product Image Figure 2. Global Ioversol Injection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ioversol Injection Market Size (2021-2032) & (US$ Million) Figure 4. Global Ioversol Injection Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. 50mL Image Figure 8. 75mL Image Figure 9. 100mL Image Figure 10. 125mL Image Figure 11. Global Ioversol Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Ioversol Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Ioversol Injection Sales Value Share by Type (2021-2032) Figure 14. Hospital Image Figure 15. Clinic Image Figure 16. Others Image Figure 17. Global Ioversol Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Ioversol Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Ioversol Injection Sales Value Share by Application (2021-2032) Figure 20. Global Ioversol Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Ioversol Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Ioversol Injection Sales Value (2021-2032) & (US$ Million) Figure 23. North America Ioversol Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Ioversol Injection Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Ioversol Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Ioversol Injection Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Ioversol Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Ioversol Injection Sales Value (2021-2032) & (US$ Million) Figure 29. South America Ioversol Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Ioversol Injection Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Ioversol Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Ioversol Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Ioversol Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Ioversol Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • 50mL
  • 75mL
  • 100mL
  • 125mL
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • GUERBET
  • Zhejiang Starry Pharmaceutical
  • Hengrui Pharmaceuticals
  • Bayer HealthCare Pharmaceuticals
  • Neptunus Bio-pharmaceutical
  • Liebel-Flarsheim Company LLC
  • Bracco Imaging S.p.A.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Ioversol Injection Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Ioversol Injection Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Ioversol Injection Market Dynamics
  1. 2.1 Ioversol Injection Industry Trends
  2. 2.2 Ioversol Injection Industry Drivers
  3. 2.3 Ioversol Injection Industry Opportunities and Challenges
  4. 2.4 Ioversol Injection Industry Restraints
3 Ioversol Injection Market by Company
  1. 3.1 Global Ioversol Injection Company Revenue Ranking in 2025
  2. 3.2 Global Ioversol Injection Revenue by Company (2021-2026)
  3. 3.3 Global Ioversol Injection Company Ranking (2024-2026)
  4. 3.4 Global Ioversol Injection Company Manufacturing Base and Headquarters
  5. 3.5 Global Ioversol Injection Company Product Type and Application
  6. 3.6 Global Ioversol Injection Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Ioversol Injection Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Ioversol Injection Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Ioversol Injection Market by Type
  1. 4.1 Ioversol Injection Type Introduction
  2. 4.1.1 50mL
  3. 4.1.2 75mL
  4. 4.1.3 100mL
  5. 4.1.4 125mL
  6. 4.2 Global Ioversol Injection Sales Value by Type
  7. 4.2.1 Global Ioversol Injection Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Ioversol Injection Sales Value by Type (2021-2032)
  9. 4.2.3 Global Ioversol Injection Sales Value Share by Type (2021-2032)
5 Ioversol Injection Market by Application
  1. 5.1 Ioversol Injection Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Ioversol Injection Sales Value by Application
  6. 5.2.1 Global Ioversol Injection Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Ioversol Injection Sales Value by Application (2021-2032)
  8. 5.2.3 Global Ioversol Injection Sales Value Share by Application (2021-2032)
6 Ioversol Injection Regional Value Analysis
  1. 6.1 Global Ioversol Injection Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Ioversol Injection Sales Value by Region (2021-2032)
  3. 6.2.1 Global Ioversol Injection Sales Value by Region: 2021-2026
  4. 6.2.2 Global Ioversol Injection Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Ioversol Injection Sales Value (2021-2032)
  7. 6.3.2 North America Ioversol Injection Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Ioversol Injection Sales Value (2021-2032)
  10. 6.4.2 Europe Ioversol Injection Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Ioversol Injection Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Ioversol Injection Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Ioversol Injection Sales Value (2021-2032)
  16. 6.6.2 South America Ioversol Injection Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Ioversol Injection Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Ioversol Injection Sales Value Share by Country, 2025 VS 2032
7 Ioversol Injection Country-level Value Analysis
  1. 7.1 Global Ioversol Injection Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Ioversol Injection Sales Value by Country (2021-2032)
  3. 7.2.1 Global Ioversol Injection Sales Value by Country (2021-2026)
  4. 7.2.2 Global Ioversol Injection Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Ioversol Injection Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Ioversol Injection Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Ioversol Injection Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Ioversol Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Ioversol Injection Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Ioversol Injection Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Ioversol Injection Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Ioversol Injection Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Ioversol Injection Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Ioversol Injection Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Ioversol Injection Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Ioversol Injection Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Ioversol Injection Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Ioversol Injection Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Ioversol Injection Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Ioversol Injection Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Ioversol Injection Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Ioversol Injection Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Ioversol Injection Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Ioversol Injection Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Ioversol Injection Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Ioversol Injection Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Ioversol Injection Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Ioversol Injection Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Ioversol Injection Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Ioversol Injection Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Ioversol Injection Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Ioversol Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Ioversol Injection Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Ioversol Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Ioversol Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GUERBET
  2. 8.1.1 GUERBET Company Information
  3. 8.1.2 GUERBET Business Overview
  4. 8.1.3 GUERBET Ioversol Injection Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GUERBET Ioversol Injection Product Portfolio
  6. 8.1.5 GUERBET Recent Developments
  7. 8.2 Zhejiang Starry Pharmaceutical
  8. 8.2.1 Zhejiang Starry Pharmaceutical Company Information
  9. 8.2.2 Zhejiang Starry Pharmaceutical Business Overview
  10. 8.2.3 Zhejiang Starry Pharmaceutical Ioversol Injection Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Zhejiang Starry Pharmaceutical Ioversol Injection Product Portfolio
  12. 8.2.5 Zhejiang Starry Pharmaceutical Recent Developments
  13. 8.3 Hengrui Pharmaceuticals
  14. 8.3.1 Hengrui Pharmaceuticals Company Information
  15. 8.3.2 Hengrui Pharmaceuticals Business Overview
  16. 8.3.3 Hengrui Pharmaceuticals Ioversol Injection Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Hengrui Pharmaceuticals Ioversol Injection Product Portfolio
  18. 8.3.5 Hengrui Pharmaceuticals Recent Developments
  19. 8.4 Bayer HealthCare Pharmaceuticals
  20. 8.4.1 Bayer HealthCare Pharmaceuticals Company Information
  21. 8.4.2 Bayer HealthCare Pharmaceuticals Business Overview
  22. 8.4.3 Bayer HealthCare Pharmaceuticals Ioversol Injection Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bayer HealthCare Pharmaceuticals Ioversol Injection Product Portfolio
  24. 8.4.5 Bayer HealthCare Pharmaceuticals Recent Developments
  25. 8.5 Neptunus Bio-pharmaceutical
  26. 8.5.1 Neptunus Bio-pharmaceutical Company Information
  27. 8.5.2 Neptunus Bio-pharmaceutical Business Overview
  28. 8.5.3 Neptunus Bio-pharmaceutical Ioversol Injection Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Neptunus Bio-pharmaceutical Ioversol Injection Product Portfolio
  30. 8.5.5 Neptunus Bio-pharmaceutical Recent Developments
  31. 8.6 Liebel-Flarsheim Company LLC
  32. 8.6.1 Liebel-Flarsheim Company LLC Company Information
  33. 8.6.2 Liebel-Flarsheim Company LLC Business Overview
  34. 8.6.3 Liebel-Flarsheim Company LLC Ioversol Injection Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Liebel-Flarsheim Company LLC Ioversol Injection Product Portfolio
  36. 8.6.5 Liebel-Flarsheim Company LLC Recent Developments
  37. 8.7 Bracco Imaging S.p.A.
  38. 8.7.1 Bracco Imaging S.p.A. Company Information
  39. 8.7.2 Bracco Imaging S.p.A. Business Overview
  40. 8.7.3 Bracco Imaging S.p.A. Ioversol Injection Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bracco Imaging S.p.A. Ioversol Injection Product Portfolio
  42. 8.7.5 Bracco Imaging S.p.A. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research